| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. | Director | Common Stock | 24.9K | $799K | $32.03 | Jun 14, 2024 | Via Alma Life Sciences, LLC |
| ANAPTYSBIO, INC | Director | Common Stock | 9.93K | $199K | $20.03 | Jun 15, 2025 | Direct |
| Arcturus Therapeutics Holdings Inc. | Director | Common Stock | 3.13K | $100K | $32.03 | Jun 14, 2024 | Direct |
| ANAPTYSBIO, INC | Director | Restricted Stock Unit | 0 | $92.3K | $15.30 | Jun 15, 2025 | Direct |
| Immix Biopharma, Inc. | Director | Common Stock | 46.1K | $91.3K | $1.98 | Jun 20, 2025 | Direct |
| Immix Biopharma, Inc. | Director | Common Stock | 20K | $39.6K | $1.98 | Jun 20, 2025 | Via ALMA Life Sciences, LLC |
| ANAPTYSBIO, INC | Director | Restricted Stock Unit | 0 | $0 | $23.16 | Jun 15, 2024 | Direct |
| Arcturus Therapeutics Holdings Inc. | Director | Deferred Stock Units | 0 | $0 | $32.03 | Jun 14, 2024 | Direct |
| Transcode Therapeutics, Inc. | Director | Stock Option (right to buy) | 70K | Jun 14, 2024 | Direct | ||
| Immix Biopharma, Inc. | Director | Stock Option (Right to Buy) | 33K | Jun 20, 2025 | Direct | ||
| ANAPTYSBIO, INC | Director | Stock Option (right to buy) | 16.5K | Jan 7, 2025 | Direct | ||
| Arcturus Therapeutics Holdings Inc. | Director | Stock option (right to buy) | 15K | Jun 9, 2025 | Direct |